BioPorto (BIOPOR) - Net Assets
Based on the latest financial reports, BioPorto (BIOPOR) has net assets worth Dkr63.01 Million DKK (≈ $9.86 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Dkr93.18 Million ≈ $14.58 Million USD) and total liabilities (Dkr30.17 Million ≈ $4.72 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BIOPOR tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Dkr63.01 Million |
| % of Total Assets | 67.62% |
| Annual Growth Rate | N/A |
| 5-Year Change | 37.08% |
| 10-Year Change | 42.26% |
| Growth Volatility | 90.38 |
BioPorto - Net Assets Trend (1999–2025)
This chart illustrates how BioPorto's net assets have evolved over time, based on quarterly financial data. See BioPorto liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for BioPorto (1999–2025)
The table below shows the annual net assets of BioPorto from 1999 to 2025. For live valuation and market cap data, see BIOPOR stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Dkr63.01 Million ≈ $9.86 Million |
-7.04% |
| 2024-12-31 | Dkr67.78 Million ≈ $10.60 Million |
+12.66% |
| 2023-12-31 | Dkr60.16 Million ≈ $9.41 Million |
-14.33% |
| 2022-12-31 | Dkr70.22 Million ≈ $10.99 Million |
+52.77% |
| 2021-12-31 | Dkr45.96 Million ≈ $7.19 Million |
-54.45% |
| 2020-12-31 | Dkr100.91 Million ≈ $15.79 Million |
+298.52% |
| 2019-12-31 | Dkr25.32 Million ≈ $3.96 Million |
-54.94% |
| 2018-12-31 | Dkr56.20 Million ≈ $8.79 Million |
+0.23% |
| 2017-12-31 | Dkr56.07 Million ≈ $8.77 Million |
+26.59% |
| 2016-12-31 | Dkr44.29 Million ≈ $6.93 Million |
-0.44% |
| 2015-12-31 | Dkr44.48 Million ≈ $6.96 Million |
+55.08% |
| 2014-12-31 | Dkr28.69 Million ≈ $4.49 Million |
-33.07% |
| 2013-12-31 | Dkr42.86 Million ≈ $6.71 Million |
+3827.13% |
| 2012-12-31 | Dkr-1.15 Million ≈ $-179.93K |
-129.19% |
| 2011-12-31 | Dkr3.94 Million ≈ $616.44K |
+19.07% |
| 2010-12-31 | Dkr3.31 Million ≈ $517.72K |
-78.53% |
| 2009-12-31 | Dkr15.41 Million ≈ $2.41 Million |
-0.59% |
| 2008-12-31 | Dkr15.50 Million ≈ $2.43 Million |
-47.37% |
| 2007-12-31 | Dkr29.45 Million ≈ $4.61 Million |
+267.21% |
| 2006-12-31 | Dkr-17.62 Million ≈ $-2.76 Million |
-476.44% |
| 2005-12-31 | Dkr-3.06 Million ≈ $-478.13K |
-104.56% |
| 2004-12-31 | Dkr66.97 Million ≈ $10.48 Million |
+0.59% |
| 2003-12-31 | Dkr66.58 Million ≈ $10.42 Million |
+3151.10% |
| 2002-12-31 | Dkr-2.18 Million ≈ $-341.39K |
-293.15% |
| 2001-12-31 | Dkr-555.00K ≈ $-86.83K |
-162.08% |
| 2000-12-31 | Dkr894.00K ≈ $139.87K |
+418.15% |
| 1999-12-31 | Dkr-281.00K ≈ $-43.96K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to BioPorto's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 43332400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Dkr495.11 Million | 785.78% |
| Other Comprehensive Income | Dkr1.22 Million | 1.94% |
| Total Equity | Dkr63.01 Million | 100.00% |
BioPorto Competitors by Market Cap
The table below lists competitors of BioPorto ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Streamex Corp
NASDAQ:STEX
|
$89.47 Million |
|
Fluent Inc
NASDAQ:FLNT
|
$89.50 Million |
|
KEYEAST.Co.Ltd
KQ:054780
|
$89.53 Million |
|
CAB Cakaran Corporation Bhd
KLSE:7174
|
$89.54 Million |
|
ChampionsGate Acquisition Corporation Class A Ordinary Share
NASDAQ:CHPG
|
$89.45 Million |
|
Agrify Corp
NASDAQ:AGFY
|
$89.44 Million |
|
Sarla Performance Fibers Limited
NSE:SARLAPOLY
|
$89.39 Million |
|
Ecos India Mobility & Hospitality Ltd
NSE:ECOSMOBLTY
|
$89.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioPorto's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 67,778,000 to 63,009,000, a change of -4,769,000 (-7.0%).
- Net loss of 82,117,000 reduced equity.
- New share issuances of 76,855,000 increased equity.
- Other comprehensive income increased equity by 2,276,000.
- Other factors decreased equity by 1,783,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Dkr-82.12 Million | -130.33% |
| Share Issuances | Dkr76.86 Million | +121.97% |
| Other Comprehensive Income | Dkr2.28 Million | +3.61% |
| Other Changes | Dkr-1.78 Million | -2.83% |
| Total Change | Dkr- | -7.04% |
Book Value vs Market Value Analysis
This analysis compares BioPorto's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.85x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | Dkr-0.08 | Dkr1.16 | x |
| 2006-12-31 | Dkr-0.43 | Dkr1.16 | x |
| 2007-12-31 | Dkr0.56 | Dkr1.16 | x |
| 2008-12-31 | Dkr0.24 | Dkr1.16 | x |
| 2009-12-31 | Dkr0.24 | Dkr1.16 | x |
| 2010-12-31 | Dkr0.05 | Dkr1.16 | x |
| 2011-12-31 | Dkr0.05 | Dkr1.16 | x |
| 2012-12-31 | Dkr-0.02 | Dkr1.16 | x |
| 2013-12-31 | Dkr0.43 | Dkr1.16 | x |
| 2014-12-31 | Dkr0.19 | Dkr1.16 | x |
| 2015-12-31 | Dkr0.29 | Dkr1.16 | x |
| 2016-12-31 | Dkr0.27 | Dkr1.16 | x |
| 2017-12-31 | Dkr0.31 | Dkr1.16 | x |
| 2018-12-31 | Dkr0.28 | Dkr1.16 | x |
| 2019-12-31 | Dkr0.10 | Dkr1.16 | x |
| 2020-12-31 | Dkr0.47 | Dkr1.16 | x |
| 2021-12-31 | Dkr0.17 | Dkr1.16 | x |
| 2022-12-31 | Dkr0.21 | Dkr1.16 | x |
| 2023-12-31 | Dkr0.17 | Dkr1.16 | x |
| 2024-12-31 | Dkr0.17 | Dkr1.16 | x |
| 2025-12-31 | Dkr0.12 | Dkr1.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioPorto utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -130.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -203.83%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 1.48x
- Recent ROE (-130.33%) is below the historical average (-102.07%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 0.16% | 4.99% | 0.03x | 1.21x | Dkr-6.59 Million |
| 2005 | 0.00% | -360.20% | 0.30x | 0.00x | Dkr-15.41 Million |
| 2006 | 0.00% | -305.82% | 1.16x | 0.00x | Dkr-15.22 Million |
| 2007 | -51.76% | -182.81% | 0.25x | 1.15x | Dkr-18.19 Million |
| 2008 | -92.01% | -171.03% | 0.44x | 1.24x | Dkr-15.81 Million |
| 2009 | -104.33% | -146.06% | 0.54x | 1.31x | Dkr-17.62 Million |
| 2010 | -432.15% | -103.61% | 0.66x | 6.34x | Dkr-14.63 Million |
| 2011 | -378.32% | -80.21% | 0.87x | 5.39x | Dkr-15.30 Million |
| 2012 | 0.00% | -82.32% | 0.98x | 0.00x | Dkr-14.59 Million |
| 2013 | -48.11% | -124.05% | 0.32x | 1.21x | Dkr-24.91 Million |
| 2014 | -45.06% | -69.10% | 0.50x | 1.30x | Dkr-15.79 Million |
| 2015 | -24.12% | -52.65% | 0.42x | 1.10x | Dkr-15.18 Million |
| 2016 | -51.48% | -110.04% | 0.41x | 1.14x | Dkr-27.23 Million |
| 2017 | -57.51% | -128.18% | 0.38x | 1.17x | Dkr-37.85 Million |
| 2018 | -67.70% | -146.25% | 0.39x | 1.18x | Dkr-43.67 Million |
| 2019 | -275.03% | -261.60% | 0.62x | 1.69x | Dkr-72.17 Million |
| 2020 | -61.01% | -265.31% | 0.17x | 1.39x | Dkr-71.65 Million |
| 2021 | -124.26% | -235.48% | 0.30x | 1.77x | Dkr-61.71 Million |
| 2022 | -108.12% | -262.08% | 0.27x | 1.55x | Dkr-82.95 Million |
| 2023 | -93.63% | -181.95% | 0.34x | 1.49x | Dkr-62.34 Million |
| 2024 | -100.69% | -188.29% | 0.38x | 1.42x | Dkr-75.02 Million |
| 2025 | -130.33% | -203.83% | 0.43x | 1.48x | Dkr-88.42 Million |
Industry Comparison
This section compares BioPorto's net assets metrics with peer companies in the Diagnostics & Research industry.
No peer company data available for comparison.
About BioPorto
BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination o… Read more